Our Work
Latham & Watkins Advises on Oviva’s US$80 Million Series C
September 3, 2021
London emerging companies team represents lead investor in one of Europe’s largest health tech raises to date in 2021.
Latham & Watkins advised the lead investor on its Series C investment in Oviva, a health tech startup. Oviva’s US$80 million Series C funding brings its total raised to date to US$115 million.
Oviva combines expert advice from dietitians with digital tools to help people with conditions such as type 2 diabetes improve their health. Oviva will use the new capital to scale up its business.
The Latham team was led by London partner
Mike Turner and associate Samantha Si.